DCA Unearths Spurious Medicine Racket In Vijayawada

Vijaywada : The Department of Drugs Control Administration of the State government has busted a spurious drug racket in Vijayawada.

The Drugs Inspector has established that certain drugs manufactured by reputed pharma companies are imitated, and manufactured in a manner that would deceive unsuspecting consumers. The department further learnt that the unauthorised dealers are supplying substandard medicines by falsely labelling them as products manufactured by a reputed pharma company.

These counterfeit and spurious drugs would cause severe and fatal damage to one’s health as they are not manufactured by the original drug companies. The materials used in the drugs and the conditions being maintained at the manufacturing facility are of dubious quality, and it is likely that the ingredients can be toxic and can even cause death, said B. Anvesh Reddy, Drugs Inspector, Vijayawada Zone-IV of the Drug Control Administration in his complaint lodged with the Bhavanipuram police in Vijayawada on September 6 (Wednesday). The Hindu has accessed the complaint of the Drugs Inspector, a copy of the First Information Report (FIR) and other laboratory findings related to the drug racket.

The FIR has been registered against P.D.M.K.R.G. Krishna Murthy, of Lakshmi Padmavathi Pharma at Vasavi Pharma Market Complex in Vijayawada, and N. Kiran Kumar of Vidyadharapuram in Vijayawada under Sections 420 (cheating and dishonestly inducing delivery of property), 471 (using as genuine a forged document), 274 (adulteration of drugs) and 275 (selling adulterated drugs) of the Indian Penal Code (IPC).

Related Posts

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

US market to dent India pharma earnings even as domestic growth remains firm

US market to dent India pharma earnings even as domestic growth remains firm

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg